GREECE

Kani C. Prinea E. Alexopoulou E.
PHARMACISTS, MSc, PhD
EOPYY DIVISION OF PHARMACY

Recent and planned developments in pharmaceutical policies 2025/2026

CHANGES IN PRICING	CHANGES IN REIMBURSEMENT
The clawback mechanism is extended until 2030. No other significant changes during 2025 & 2026.	• Introduction of 3 positive lists during 2025, one positive list during 2026 (February 20, 2026) • Patients with a visual impairment of 80% or more do not pay a co-payment for all medications administered to treat their condition (by end of September 2025) • SPC filters in Multiple Sclerosis products (2026)

OTHER CHANGES

- **Home Delivery of High-Cost Medicines**

A home delivery service for high-cost medicines through a certified Third-Party Logistics (3PL) provider is established. All medicines are dispensed by EOPYY. This initiative is designed to facilitate access for vulnerable patient groups, improve treatment adherence, and reduce the need for physical presence at EOPYY distribution points.

- **Decentralized Distribution through Private Pharmacies**

A structured framework for the distribution of specific categories of high cost medicines via private pharmacies has been developed, whereby all medicines are dispensed by EOPYY and delivered on its behalf to designated private pharmacies. Patients will be able to collect their medicines from these pharmacies, enhancing accessibility and geographical coverage. Private pharmacists will be appropriately remunerated for their role in the final-stage service provision, ensuring high-quality patient support and continuity of care.

- **Digital Transformation of EOPYY**

The digital transformation of EOPYY through the integration of advanced technologies has been activated, including artificial intelligence (AI), electronic invoicing, and comprehensive digital patient records.

- **Application of EOPYY for membership registration at International Horizon Scanning Initiative (IHSI)**

Application for Membership registration of EOPYY_GREECE as a Joined member of the Association IHSI, complementing EOPYY by early identification of medicines with potential budget impact.

SPECIAL TOPIC:
Regulation, pricing and reimbursement of pharmaceutical combination products

Regulation in accordance with the current legal EU framework (Directive 2001/83/EC "on the Community code relating to medicinal products for human use").

Rules for pricing and repricing of active ingredient combinations (November 29, 2024)

1. During the first pricing of medicines with known active ingredients, it is required that the specific pharmaceutical form, strength and packaging have been priced in at least three (3) Eurozone member states. The maximum net producer price (ex-factory) is defined as the average (MO) of the two (2) lowest different prices in the Eurozone member states for the same medicine, in terms of active ingredients, pharmaceutical form, strength and packaging (nine-digit E.O.F. code). The rules and methodology of the provisions of Article 4 of this Regulation shall apply to the determination of the price. In case that the prices found are the same in all Eurozone countries where a price has been found, the medicine shall receive this price, provided that the condition of paragraph 1 is met.

2.When repricing a medicine falling within the scope of this article, the maximum net producer price (ex-factory) shall be determined in the same way as the rules and methodology applied during its first pricing in accordance with the provisions of this article. In case that a price is available in only one Eurozone Member State for the nine-digit EOF code of the medicine, for the selection of the second lowest price, reference shall be made to the nearest packaging and/or content in accordance with article 15 of this article, and the average of these two prices shall be selected.

For different packages or strengths of a drug of the same pharmaceutical form, the price is found using the procedure in the previous paragraphs.

3. The price of drugs with combinations of known active substances is reduced in each repricing after the effective date of this by up to 7% of the price of the immediately preceding price list, provided that their price in the immediately preceding price list is higher than the average of the two lowest different prices of the Eurozone member states, and with a minimum of the average of the two lowest different prices of the Eurozone member states. Drugs with combinations of active substances with a Daily Treatment Cost less than or equal to 0.33 euros are not repriced. The prices of medicines containing combinations of active substances whose Daily Treatment Cost during the repricing is lower than 0.33 euros shall be reduced up to this limit.